Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN.
Cohen JA, et al.
Arch Neurol. 2001 Jun;58(6):961-7. doi: 10.1001/archneur.58.6.961.
Arch Neurol. 2001.
PMID: 11405811
Clinical Trial.